Currently out of the existing stock ratings of Dennis Ding, 11 are a BUY (68.75%), 5 are a HOLD (31.25%).

Dennis Ding

Work Performance Price Targets & Ratings Chart

Analyst Dennis Ding, currently employed at JEFFERIES, carries an average stock price target met ratio of 59.38% that have a potential upside of 29.25% achieved within 146 days.

Dennis Ding’s has documented 32 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 18-Sep-2025.

Wall Street Analyst Dennis Ding

Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) at 10/17/2022. The price target of $4 was fulfilled within 3 days with a profit of $0.59 (17.3%) receiving and performance score of 57.67.

Average potential price target upside

of $2.2 (22.75%) on ROIV (ROIVANT SCIENCES LTD).
of $11 (52.38%) on LYRA (LYRA THERAPEUTICS ).
of $5.94 (20.44%) on CORT (CORCEPT THERAPEUTICS).

ABUS Arbutus Biopharma Corp NGM NGM Biopharmaceuticals PRDS Pardes Biosciences ROIV Roivant Sciences Ltd CINC CinCor Pharma CORT Corcept Therapeutics LYRA Lyra Therapeutics SGTX Sigilon Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)